Foundation Medicine, Inc., a genomics company dedicated to transforming cancer care, today announced that research from its robust oncology diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California April 5-10, 2024.
The presentations include new research from Foundation Medicine's two circulating tumor DNA (ctDNA) monitoring tests ? FoundationOne®Tracker and the research use version of FoundationOne®Monitor ? demonstrating the value of the company's diverse portfolio of tissue-informed and tissue-naïve assays to support cancer treatment response monitoring. Highlights include:
Additional presentations focused on the value of genomic profiling in non-small cell lung cancer (NSCLC) include data on how tumor microenvironment (TME) impacts immunotherapy response and an ancestry-based genomic landscape study. Highlights include:
"We're excited to present new data at AACR reinforcing the diverse utility of our monitoring portfolio to help confirm that patients are on the right targeted therapies and immunotherapies for the right amount of time," says Mia Levy, MD, PhD, Chief Medical Officer at Foundation Medicine. "Additionally, we know that the impact of genetic ancestry on the genomic landscape of tumors remains understudied, and we are always proud to demonstrate our dedication to closing more gaps in these disparities in cancer care."
Additionally, Dr. Levy will be taking part in a plenary session on Wednesday, April 10 titled "AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design." The following is a list of the presentations, along with their viewing details. To access all abstracts being presented at AACR, please visit aacr.org.
Follow Foundation Medicine on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #3117.
Abstract # |
Title |
Collaborator |
Product |
Mini Symposium |
|||
April 7 3:35 ? 3:50 p.m.
|
Tumor-Informed Circulating Tumor DNA Monitoring for Early Treatment Response and Survival Outcomes on Trastuzumab + Pertuzumab |
Genentech, Natera MCW Cancer Center, University of Adelaide Sarah Cannon Research Institute, MD Anderson Cancer Center, Francis Crick Institute |
FoundationOne®Tracker |
Posters |
|||
April 7 1:30 ? 5:00 p.m. |
Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC) |
Genentech, Yale School of Medicine,?Alabama Oncology, New York Cancer and Blood Specialists
|
FoundationOne®Monitor for research use |
April 9 9:00 a.m. ? 12:00 p.m.
|
Investigating digital pathology tumor microenvironment features for immunotherapy outcome in patients with advanced non-small cell lung cancer |
|
Foundation Medicine & Flatiron Health's Joint Clinico-Genomic Database |
April 9 1:30 ? 5:00 p.m. |
Genomic profiling of KRAS and EGFR-altered non-squamous non-small cell lung cancer reveal ancestry-specific co-alterations with therapeutic implications |
Genentech |
FoundationOne FoundationOne®CDX |
About Foundation Medicine: Your Essential Partner in Cancer Care
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
These press releases may also interest you
|